TY  - RPRT
TI  - Belgian guidelines for economic evaluations and budget impact analyses: third edition
AU  - Neyt Mattias
AU  - Thiry Nancy
AU  - Cleemput Irina
AB  - KCE Reports 400C (2025)
In Belgium, cost-effectiveness is one of the criteria used by public authorities to assess applications for reimbursement of medicines and Class 1 medical devices, i.e. products for which the applicant claims added therapeutic value and for which a higher price may be charged.
T2  - KCE Reports
CY  - Brussels
PY  - 2025
LA  - English
M3  - Method
PB  - Belgian Health Care Knowledge Centre (KCE)
SN  - 400C
VO  - D/2025/10.273/05
DO  - https://doi.org/10.57598/R400C
ER -